Pituitary Adenylate Cyclase Activating Polypeptide Has Inhibitory Effects on Melanoma Cell Proliferation and Migration
PACAP receptors
invasion
melanocyte
melanoma
migration
proliferation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
19
08
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Pituitary adenylate cyclase activating polypeptide (PACAP) is an endogenous neuropeptide which is distributed throughout the body. PACAP influences development of various tissues and exerts protective function during cellular stress and in some tumour formation. No evidence is available on its role in neural crest derived melanocytes and its malignant transformation into melanoma. Expression of PACAP receptors was examined in human skin samples, melanoma lesions and in a primary melanocyte cell culture. A2058 and WM35 melanoma cell lines, representing two different stages of melanoma progression, were used to investigate the effects of PACAP. PAC1 receptor was identified in melanocytes
Identifiants
pubmed: 34616669
doi: 10.3389/fonc.2021.681603
pmc: PMC8488289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
681603Informations de copyright
Copyright © 2021 Hajdú, Kovács, Zsigrai, Takács, Vágó, Cho, Sasi-Szabó, Becsky, Keller-Pinter, Emri, Rácz, Reglodi, Zákány and Juhász.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors contributed to the article and approved the submitted version.
Références
Peptides. 2015 Apr;66:26-42
pubmed: 25698233
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47
pubmed: 26702849
J Mol Neurosci. 2019 Jul;68(3):408-419
pubmed: 30443839
FEBS Lett. 2000 Jun 16;475(2):78-83
pubmed: 10858492
Int J Mol Sci. 2018 Aug 27;19(9):
pubmed: 30150589
Peptides. 2010 Nov;31(11):2035-45
pubmed: 20691743
Br J Pharmacol. 2013 Jun;169(3):512-23
pubmed: 23517078
Biochem Biophys Res Commun. 1990 Jul 31;170(2):643-8
pubmed: 2383262
Pigment Cell Melanoma Res. 2014 Nov;27(6):1014-31
pubmed: 25104547
J Mol Neurosci. 2014 Nov;54(3):555-73
pubmed: 25112418
Neurosci Lett. 2012 Aug 15;523(2):93-8
pubmed: 22750211
J Mol Neurosci. 2019 Jul;68(3):475-484
pubmed: 30993644
J Mol Neurosci. 2016 Jun;59(2):203-10
pubmed: 26646243
J Mol Neurosci. 2021 Aug;71(8):1589-1597
pubmed: 32964398
Cell Signal. 2018 Oct;50:37-47
pubmed: 29935235
Drug Discov Today. 2019 Nov;24(11):2192-2201
pubmed: 31520747
Pathology. 2016 Feb;48(2):147-54
pubmed: 27020387
Neurosci Lett. 2013 Aug 9;549:92-6
pubmed: 23792266
Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
pubmed: 2803320
J Investig Dermatol Symp Proc. 2005 Nov;10(2):153-63
pubmed: 16358819
PLoS One. 2013 Sep 09;8(9):e72607
pubmed: 24039785
Pigment Cell Res. 1994 Feb;7(1):33-43
pubmed: 8072944
J Invest Dermatol. 2010 Jul;130(7):1893-903
pubmed: 20357818
Cancers (Basel). 2019 Jan 21;11(1):
pubmed: 30669581
FEBS Lett. 2014 Dec 20;588(24):4730-9
pubmed: 25451228
Nature. 2007 Feb 22;445(7130):843-50
pubmed: 17314970
Peptides. 2007 Sep;28(9):1713-9
pubmed: 17719696
Peptides. 2007 Sep;28(9):1746-52
pubmed: 17544170
Mayo Clin Proc. 2006 Apr;81(4):500-7
pubmed: 16610570
J Invest Dermatol. 2015 Sep;135(9):2209-2218
pubmed: 25905588
Cell Mol Life Sci. 2019 May;76(10):1919-1934
pubmed: 30830237
Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23
pubmed: 21080806
Int J Mol Sci. 2018 Jun 30;19(7):
pubmed: 29966365
J Dermatol Sci. 1998 May;20(1):21-8
pubmed: 10342745
Cancer Treat Res. 2016;167:107-29
pubmed: 26601860
Traffic. 2009 Jul;10(7):938-50
pubmed: 19416476
Int J Mol Sci. 2020 Jan 27;21(3):
pubmed: 32012800
Neuropeptides. 2010 Oct;44(5):373-83
pubmed: 20638719
Pharmacol Rev. 2009 Sep;61(3):283-357
pubmed: 19805477
Geroscience. 2019 Dec;41(6):775-793
pubmed: 31655957
J Mol Neurosci. 2019 Jul;68(3):439-451
pubmed: 30058008
J Mol Neurosci. 2019 Jul;68(3):340-347
pubmed: 30054797
N Engl J Med. 2006 Jul 6;355(1):51-65
pubmed: 16822996
Cancers (Basel). 2020 Jul 07;12(7):
pubmed: 32645881
Int J Mol Sci. 2019 Jan 04;20(1):
pubmed: 30621194
J Mol Histol. 2004 Mar;35(3):309-18
pubmed: 15339050
Int J Mol Sci. 2019 Oct 07;20(19):
pubmed: 31591326
Cancers (Basel). 2020 May 22;12(5):
pubmed: 32455916
Regul Pept. 2006 Nov 15;137(1-2):50-7
pubmed: 17011642
Curr Protoc Cell Biol. 2014 Jun 03;63:1.8.1-20
pubmed: 24894835
Int J Mol Sci. 2020 Jun 27;21(13):
pubmed: 32605090
EMBO Rep. 2000 Nov;1(5):411-5
pubmed: 11258480
Front Endocrinol (Lausanne). 2020 Jul 14;11:377
pubmed: 32765418
Curr Pharm Des. 2011;17(10):1002-24
pubmed: 21524253
Br J Dermatol. 2017 Feb;176(2):413-422
pubmed: 27453364
Am J Physiol Cell Physiol. 2018 Feb 1;314(2):C233-C241
pubmed: 29141923
Cerebellum. 2009 Dec;8(4):433-40
pubmed: 19548046
PLoS One. 2014 Mar 18;9(3):e91541
pubmed: 24643018
J Invest Dermatol. 2018 Jul;138(7):1591-1600
pubmed: 29428355
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900
pubmed: 17392427
J Neurochem. 2008 Jan;104(1):74-88
pubmed: 17995938
J Mol Neurosci. 2009 Nov;39(3):391-401
pubmed: 19701709
Dermatology. 2019;235(3):175-186
pubmed: 30808842
Geroscience. 2018 Dec;40(5-6):437-452
pubmed: 30345481
Endocrine. 2004 Feb;23(1):59-75
pubmed: 15034198
BMB Rep. 2014 Jul;47(7):369-75
pubmed: 24856828
J Mol Neurosci. 2014 Nov;54(3):388-94
pubmed: 25091859
Int J Mol Sci. 2018 Mar 29;19(4):
pubmed: 29596316